Tollys closes pre-Series A financing of €2.3 million
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Recent Posts
- TL-532, a novel rationally designed TLR3 agonist, induces tumor-specific apoptosis, immune simulation, life-long anti-tumor auto-vaccination, and reverses resistance to immune checkpoint inhibitors
- Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532
- TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
- TL-532 specific TLR3 agonist induces lifelong anti-tumor autovaccination, cross-immunity against unrelated cancer and reverses resistance to immune checkpoint inhibitors
- TOLLYS : la phase clinique bientôt en vue (La Gazette du Laboratoire – Juillet 2022)
Archives
- October 2022
- September 2022
- July 2022
- March 2022
- February 2022
- January 2022
- December 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- October 2020
- July 2020
- May 2020
- December 2019
- November 2019
- August 2018
- June 2016
- January 2015
- September 2012
- March 2011
- December 2007
- August 2007
- April 2006
- September 1991
- July 1980
Recent Comments